Joshua K. Sabari, MD

Articles

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

December 21st 2023

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

December 21st 2023

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

December 20th 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

December 20th 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

December 15th 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

December 15th 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Disease Progression Beyond Frontline KRAS G12C Inhibitors

December 14th 2023

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

December 14th 2023

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

December 7th 2023

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

December 7th 2023

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

December 6th 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

December 6th 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Frontline Treatments for KRAS G12C-Mutation mNSCLC

November 30th 2023

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

The State of Targeted Therapies in NSCLC

November 30th 2023

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

November 29th 2023

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

November 29th 2023

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

November 22nd 2023

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

NSCLC: PD-L1 Expression and Treatment Decision-Making

November 22nd 2023

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

The Role of CTLA-4 Inhibitors in NSCLC

November 15th 2023

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

November 15th 2023

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).